

# Products And Their Use In Specific Cancers

Do I need the capsule, transdermal or liquid formulation of Tumexal™?

Because the majority of cancers have inactivating mutations in the p53 tumor suppressor gene, and Tumexal™'s mechanism of action is to restore p53 function to the cancer cell, Tumexal™ is active against a wide array of cancer types. Nevertheless, different cancers have differing biologies, and can best be treated with specific formulations of Tumexal™. For example, osteosarcoma (bone cancer) must be treated as two entirely different types of cancer with two entirely different biologies. By the time a primary osteosarcoma can be clinically diagnosed, in virtually 100% of cases it has already spread to the lungs, even if such micrometastases cannot be seen on X-ray. It is impossible, using one treatment modality, to treat both the primary osteosarcoma and the pulmonary metastases that have spread from it. The capsule formulation of Tumexal™, when used continuously for three months and intermittently after that, has shown a quite remarkable ability to eliminate pulmonary metastases and to prevent new ones from growing in the lung. But the capsule formulation appears to be ineffective in stopping the growth of primary osteosarcoma tumors—probably because they secrete little angiogenesis factor and therefore do not have the well-developed blood supply that other kinds of solid tumors possess. While amputation is the surest way to eliminate a primary osteosarcoma, many dog owners refuse such surgery for their animals, and in other cases amputation is not possible. To help in such cases, CanineCare.US has created a transdermal formulation of Tumexal™ that is applied, as a cream, directly to the site of the primary tumor. Up to 90% of the Tumexal™ in this formulation passes through the skin and creates a very high local concentration at the site of the primary tumor, where it is needed. Using this formulation, the growth of the primary tumor can generally be stopped.

The transdermal formulation of Tumexal™ can also be used in cases where dogs are not eating or are unable to eat, for example in certain cases of oral or head and neck cancer; in various cancers of the skin including cutaneous T cell lymphoma (mycoses fungoides) and mast cell cancer; in anal gland cancer, etc. If you have questions about application in your dog's specific case, you may address those questions to our cancer specialist either by telephone (610-833-8136) or email ([doc@caninecare.us](mailto:doc@caninecare.us)).

We also have a liquid formulation of Tumexal™ for dogs that may be too small to swallow size 0 capsules.

Below is a listing of various forms of canine cancer, and the formulation(s) of Tumexal™ used to treat them. Again, if you have questions, please feel free to address them to the telephone number or email address noted above.

Anal Gland Cancer-Capsule formulation ± transdermal formulation

Bladder Cancer (transitional cell carcinoma)-Capsule formulation ± transdermal formulation

Hemangiosarcoma-Capsule formulation, modified to control risk of bleeding

Lymphoma (lymphosarcoma)-Capsule formulation (liquid formulation for small dogs under 12 pounds).

Leukemia (chronic or acute, lymphocytic or granulocytic)-Capsule formulation (liquid formulation for small dogs under 12 pounds).

Osteosarcoma-Capsule formulation alone if primary is amputated. Capsules + transdermal if amputation is not being considered.

Mast Cell Cancer-Transdermal ± capsules.

Cutaneous T cell lymphoma (mycoses fungoides).-Transdermal ± capsules.

Mammary Carcinoma-Transdermal ± capsules.

Sarcoma, various-Capsule formulation ± transdermal formulation.

Nasal Cavity Cancer-Capsule formulation ± transdermal formulation.

Squamous Cell Carcinoma-Transdermal ± capsules.

Link: <http://caninecare.us/products/>